Search results
Ivonescimab Monotherapy Decisively Beats Pembrolizumab Monotherapy Head-to-Head, Achieves...
The Pilot News· 7 days agoAkeso, Inc. (HKEX: 9926.HK) ("Akeso," "we," or the "Company") today announced that the Phase III clinical trial, HARMONi-2 or AK112-303, met its primary endpoint of progression-free survival ...
Summit Therapeutics' Lung Cancer Therapy Ivonescimab Shows Improved Progression-Free Survival Versus...
Benzinga via Yahoo Finance· 6 days agoThursday, Summit Therapeutics Inc (NASDAQ:SMMT) announced that Phase 3 HARMONi-2, or AK112-303, met...
Immunotherapy significantly increases the number of patients free from bowel cancer: Clinical trial
Medical Xpress· 4 days agoThe trial was a collaboration among UCL, UCLH, the Christie NHS Foundation Trust in Manchester...
...Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab...
The Morning Sun· 5 days agoCOPENHAGEN, Denmark & MAINZ, Germany--(BUSINESS WIRE)--Jun 1, 2024--Genmab A/S(Nasdaq: GMAB) andBioNTech SE(Nasdaq: BNTX) today announced initial data from the Phase 2 GCT1046-04 trial ( …
Health Care Roundup: Market Talk
The Wall Street Journal· 7 days agoSummit Therapeutics says its monotherapy ivonescimab outperformed pembrolizumab, sold under brand name Keytruda, in a Phase 3 trial involving lung-cancer...
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 5 days agoThe results showed a 12-month overall survival (“...
Genmab and BioNTech report data from Phase II GCT1046-04 trial for mNSCLC
Clinical Trials Arena via Yahoo Finance· 3 days agoThe GCT1046-04 clinical trial is an open-label study evaluating the safety and efficacy of...
Summit reports data from Phase III NSCLC treatment trial
Clinical Trials Arena via Yahoo Finance· 6 days agoSponsored and analysed by Akeso, the single-region, multicentre, double-blinded trial assessed...
Promising HPV Cancer Treatment Advances in Clinical Trial By Investing.com
Investing.com· 2 days agoHOOKIPA Pharma Inc. (NASDAQ: HOOK), a clinical-stage biopharmaceutical company, has reported...
Ivonescimab shows promise in NSCLC Phase III trial By Investing.com
Investing.com· 7 days agoSummit Therapeutics Inc. (NASDAQ: NASDAQ:SMMT) announced that its Phase III clinical trial,...